 Fortress Biotech, Inc. Common Stock: Nasdaq: FBIO Preferred Stock: Nasdaq: FBIOP Fortress, an innovative biopharmaceutical company, today announced that it has priced an underwritten public offering of 555,556 shares of its 9.375 Series A Cumulative Redeemable Perpetual Preferred Stock Series A Preferred Stock at a price of 18.00 per share, with expected gross proceeds to Fortress of approximately 10 million. In addition, Fortress has granted the underwriters a 45-day option to purchase up to 83,333 additional shares of its Series A Preferred Stock at the public offering price, less underwriting discounts and commissions. 